Acute Myelogenous Leukemia in Childhood: Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies
The results of treatment for childhood acute myelogenous leukemia (AML) have improved considerably during the last ten years. This progress was demonstrated by the two consecutive multicenter studies, AML-BFM-78 and -83, in which almost identical extended multi drug regimes of che motherapy were ad...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1990
|
| Schlagworte: | |
| Online-Zugang: | UBR01 URL des Erstveröffentlichers |
| Zusammenfassung: | The results of treatment for childhood acute myelogenous leukemia (AML) have improved considerably during the last ten years. This progress was demonstrated by the two consecutive multicenter studies, AML-BFM-78 and -83, in which almost identical extended multi drug regimes of che motherapy were administered for eight weeks and followed up by two years maintenance. The main difference in the second study was the addition of an eight-day intensive in duction course. Due to this new element, the relapse rate was reduced significantly. Another result of the BFM-83 study was the definition of two risk groups on the basis of standardized treatment, which has lead to a risk-adapted treatment strategy in the third ongoing trial, AML-BFM- 87. This improvement was only possible thanks to the coop eration of pediatricians, physicians, radiotherapists, statisti cians, and especially the staff at the hospitals and reference laboratories. Thus, we would like to thank everyone who has been involved in these studies and hope that they will be further encouraged to improve treatment strategies for AML in children. The coordination, enforcement, and analyses of the stud ies would not have been possible without the financial sup port of the Federal Ministry for Research and Technology of the FRG. We are grateful for the generous contributions supporting this book from Lederle and Farmitalia. Munster, April 1990 Ursula Creutzig Jorg Ritter Gunther Schellong Contents 1 Introduction . . . . .. . . . . . . . . . . . . . . .. . . . 1 |
| Beschreibung: | 1 Online-Ressource (XVI, 163 p. 3 illus) |
| ISBN: | 9783642753510 |
| DOI: | 10.1007/978-3-642-75351-0 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046147374 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1990 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642753510 |9 978-3-642-75351-0 | ||
| 024 | 7 | |a 10.1007/978-3-642-75351-0 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-75351-0 | ||
| 035 | |a (OCoLC)1118989172 | ||
| 035 | |a (DE-599)BVBBV046147374 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 618.92 |2 23 | |
| 245 | 1 | 0 | |a Acute Myelogenous Leukemia in Childhood |b Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies |c edited by Ursula Creutzig, Jörg Ritter, Günther Schellong |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 1990 | |
| 300 | |a 1 Online-Ressource (XVI, 163 p. 3 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a The results of treatment for childhood acute myelogenous leukemia (AML) have improved considerably during the last ten years. This progress was demonstrated by the two consecutive multicenter studies, AML-BFM-78 and -83, in which almost identical extended multi drug regimes of che motherapy were administered for eight weeks and followed up by two years maintenance. The main difference in the second study was the addition of an eight-day intensive in duction course. Due to this new element, the relapse rate was reduced significantly. Another result of the BFM-83 study was the definition of two risk groups on the basis of standardized treatment, which has lead to a risk-adapted treatment strategy in the third ongoing trial, AML-BFM- 87. This improvement was only possible thanks to the coop eration of pediatricians, physicians, radiotherapists, statisti cians, and especially the staff at the hospitals and reference laboratories. Thus, we would like to thank everyone who has been involved in these studies and hope that they will be further encouraged to improve treatment strategies for AML in children. The coordination, enforcement, and analyses of the stud ies would not have been possible without the financial sup port of the Federal Ministry for Research and Technology of the FRG. We are grateful for the generous contributions supporting this book from Lederle and Farmitalia. Munster, April 1990 Ursula Creutzig Jorg Ritter Gunther Schellong Contents 1 Introduction . . . . .. . . . . . . . . . . . . . . .. . . . 1 | ||
| 650 | 4 | |a Pediatrics | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Pediatrics | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Hematology | |
| 650 | 0 | 7 | |a Therapieplan |0 (DE-588)4121771-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Kind |0 (DE-588)4030550-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Akute myeloische Leukämie |0 (DE-588)4245523-6 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Kind |0 (DE-588)4030550-8 |D s |
| 689 | 0 | 1 | |a Akute myeloische Leukämie |0 (DE-588)4245523-6 |D s |
| 689 | 0 | 2 | |a Therapieplan |0 (DE-588)4121771-8 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Creutzig, Ursula |4 edt | |
| 700 | 1 | |a Ritter, Jörg |4 edt | |
| 700 | 1 | |a Schellong, Günther |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540520702 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642753527 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-75351-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031527559 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-75351-0 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180486654787584 |
|---|---|
| any_adam_object | |
| author2 | Creutzig, Ursula Ritter, Jörg Schellong, Günther |
| author2_role | edt edt edt |
| author2_variant | u c uc j r jr g s gs |
| author_facet | Creutzig, Ursula Ritter, Jörg Schellong, Günther |
| building | Verbundindex |
| bvnumber | BV046147374 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-75351-0 (OCoLC)1118989172 (DE-599)BVBBV046147374 |
| dewey-full | 618.92 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 618 - Gynecology, obstetrics, pediatrics, geriatrics |
| dewey-raw | 618.92 |
| dewey-search | 618.92 |
| dewey-sort | 3618.92 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-75351-0 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03593nmm a2200553zc 4500</leader><controlfield tag="001">BV046147374</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1990 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642753510</subfield><subfield code="9">978-3-642-75351-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-75351-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-75351-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118989172</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046147374</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">618.92</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Acute Myelogenous Leukemia in Childhood</subfield><subfield code="b">Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies</subfield><subfield code="c">edited by Ursula Creutzig, Jörg Ritter, Günther Schellong</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">1990</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XVI, 163 p. 3 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The results of treatment for childhood acute myelogenous leukemia (AML) have improved considerably during the last ten years. This progress was demonstrated by the two consecutive multicenter studies, AML-BFM-78 and -83, in which almost identical extended multi drug regimes of che motherapy were administered for eight weeks and followed up by two years maintenance. The main difference in the second study was the addition of an eight-day intensive in duction course. Due to this new element, the relapse rate was reduced significantly. Another result of the BFM-83 study was the definition of two risk groups on the basis of standardized treatment, which has lead to a risk-adapted treatment strategy in the third ongoing trial, AML-BFM- 87. This improvement was only possible thanks to the coop eration of pediatricians, physicians, radiotherapists, statisti cians, and especially the staff at the hospitals and reference laboratories. Thus, we would like to thank everyone who has been involved in these studies and hope that they will be further encouraged to improve treatment strategies for AML in children. The coordination, enforcement, and analyses of the stud ies would not have been possible without the financial sup port of the Federal Ministry for Research and Technology of the FRG. We are grateful for the generous contributions supporting this book from Lederle and Farmitalia. Munster, April 1990 Ursula Creutzig Jorg Ritter Gunther Schellong Contents 1 Introduction . . . . .. . . . . . . . . . . . . . . .. . . . 1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapieplan</subfield><subfield code="0">(DE-588)4121771-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kind</subfield><subfield code="0">(DE-588)4030550-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Akute myeloische Leukämie</subfield><subfield code="0">(DE-588)4245523-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Kind</subfield><subfield code="0">(DE-588)4030550-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Akute myeloische Leukämie</subfield><subfield code="0">(DE-588)4245523-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Therapieplan</subfield><subfield code="0">(DE-588)4121771-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Creutzig, Ursula</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ritter, Jörg</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schellong, Günther</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540520702</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642753527</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-75351-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031527559</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-75351-0</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046147374 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:32Z |
| institution | BVB |
| isbn | 9783642753510 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031527559 |
| oclc_num | 1118989172 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XVI, 163 p. 3 illus) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1990 |
| publishDateSearch | 1990 |
| publishDateSort | 1990 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| spelling | Acute Myelogenous Leukemia in Childhood Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies edited by Ursula Creutzig, Jörg Ritter, Günther Schellong Berlin, Heidelberg Springer Berlin Heidelberg 1990 1 Online-Ressource (XVI, 163 p. 3 illus) txt rdacontent c rdamedia cr rdacarrier The results of treatment for childhood acute myelogenous leukemia (AML) have improved considerably during the last ten years. This progress was demonstrated by the two consecutive multicenter studies, AML-BFM-78 and -83, in which almost identical extended multi drug regimes of che motherapy were administered for eight weeks and followed up by two years maintenance. The main difference in the second study was the addition of an eight-day intensive in duction course. Due to this new element, the relapse rate was reduced significantly. Another result of the BFM-83 study was the definition of two risk groups on the basis of standardized treatment, which has lead to a risk-adapted treatment strategy in the third ongoing trial, AML-BFM- 87. This improvement was only possible thanks to the coop eration of pediatricians, physicians, radiotherapists, statisti cians, and especially the staff at the hospitals and reference laboratories. Thus, we would like to thank everyone who has been involved in these studies and hope that they will be further encouraged to improve treatment strategies for AML in children. The coordination, enforcement, and analyses of the stud ies would not have been possible without the financial sup port of the Federal Ministry for Research and Technology of the FRG. We are grateful for the generous contributions supporting this book from Lederle and Farmitalia. Munster, April 1990 Ursula Creutzig Jorg Ritter Gunther Schellong Contents 1 Introduction . . . . .. . . . . . . . . . . . . . . .. . . . 1 Pediatrics Oncology Hematology Oncology Therapieplan (DE-588)4121771-8 gnd rswk-swf Kind (DE-588)4030550-8 gnd rswk-swf Akute myeloische Leukämie (DE-588)4245523-6 gnd rswk-swf Kind (DE-588)4030550-8 s Akute myeloische Leukämie (DE-588)4245523-6 s Therapieplan (DE-588)4121771-8 s DE-604 Creutzig, Ursula edt Ritter, Jörg edt Schellong, Günther edt Erscheint auch als Druck-Ausgabe 9783540520702 Erscheint auch als Druck-Ausgabe 9783642753527 https://doi.org/10.1007/978-3-642-75351-0 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Acute Myelogenous Leukemia in Childhood Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies Pediatrics Oncology Hematology Oncology Therapieplan (DE-588)4121771-8 gnd Kind (DE-588)4030550-8 gnd Akute myeloische Leukämie (DE-588)4245523-6 gnd |
| subject_GND | (DE-588)4121771-8 (DE-588)4030550-8 (DE-588)4245523-6 |
| title | Acute Myelogenous Leukemia in Childhood Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies |
| title_auth | Acute Myelogenous Leukemia in Childhood Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies |
| title_exact_search | Acute Myelogenous Leukemia in Childhood Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies |
| title_full | Acute Myelogenous Leukemia in Childhood Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies edited by Ursula Creutzig, Jörg Ritter, Günther Schellong |
| title_fullStr | Acute Myelogenous Leukemia in Childhood Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies edited by Ursula Creutzig, Jörg Ritter, Günther Schellong |
| title_full_unstemmed | Acute Myelogenous Leukemia in Childhood Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies edited by Ursula Creutzig, Jörg Ritter, Günther Schellong |
| title_short | Acute Myelogenous Leukemia in Childhood |
| title_sort | acute myelogenous leukemia in childhood implications of therapy studies for future risk adapted treatment strategies |
| title_sub | Implications of Therapy Studies for Future Risk-Adapted Treatment Strategies |
| topic | Pediatrics Oncology Hematology Oncology Therapieplan (DE-588)4121771-8 gnd Kind (DE-588)4030550-8 gnd Akute myeloische Leukämie (DE-588)4245523-6 gnd |
| topic_facet | Pediatrics Oncology Hematology Oncology Therapieplan Kind Akute myeloische Leukämie |
| url | https://doi.org/10.1007/978-3-642-75351-0 |
| work_keys_str_mv | AT creutzigursula acutemyelogenousleukemiainchildhoodimplicationsoftherapystudiesforfutureriskadaptedtreatmentstrategies AT ritterjorg acutemyelogenousleukemiainchildhoodimplicationsoftherapystudiesforfutureriskadaptedtreatmentstrategies AT schellonggunther acutemyelogenousleukemiainchildhoodimplicationsoftherapystudiesforfutureriskadaptedtreatmentstrategies |